Reuters logo
BRIEF-Capricor Therapeutics announces positive six-month results from randomized phase I/II hope clinical trial
2017年4月25日 / 上午10点46分 / 5 个月前

BRIEF-Capricor Therapeutics announces positive six-month results from randomized phase I/II hope clinical trial

April 25 (Reuters) - Capricor Therapeutics Inc

* Capricor Therapeutics announces positive six-month results from the randomized phase I/II hope clinical trial in duchenne muscular dystrophy

* Capricor Therapeutics Inc says CAP-1002 was generally safe and well-tolerated over initial six-month follow-up period

* Capricor Therapeutics Inc - Capricor expects to report top-line 12-month results from hope-duchenne trial in Q4 of 2017

* Capricor - patients treated with CAP-1002 demonstrated statistically-significant improvement compared to usual care controls in certain measures of cardiac, upper limb function Source text for Eikon: Further company coverage:

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below